Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
17.47
Oct 23 • 3:59 PM ET Dollar change+0.04 Percentage change(0.23%)
Aftermarket Close
17.13
Aftermarket • 7:32 PM ET Dollar change-0.34 Percentage change(-1.95%)
Index
-
Market Cap
6.24B
Enterprise Value
11.04B
Income
-171.00M
Sales
5.32B
Book/sh
17.86
Cash/sh
1.06
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
13000
IPO
May 06, 2022
P/E
-
Forward P/E
15.82
PEG
0.38
P/S
1.17
P/B
0.98
P/C
16.51
P/FCF
44.53
EV/EBITDA
13.54
EV/Sales
2.07
Quick Ratio
1.02
Current Ratio
1.55
Debt/Eq
0.80
LT Debt/Eq
0.80
Option/Short
Yes / Yes
EPS (ttm)
-0.48
EPS next Y
1.10
EPS next Q
0.21
EPS this Y
55.79%
EPS next Y
39.01%
EPS next 5Y
41.94%
EPS past 3/5Y
- -
Sales past 3/5Y
10.62% 8.38%
EPS Y/Y TTM
37.70%
Sales Y/Y TTM
8.85%
EPS Q/Q
77.64%
Sales Q/Q
9.08%
Insider Own
88.79%
Insider Trans
-0.02%
Inst Own
10.12%
Inst Trans
-0.53%
ROA
-1.24%
ROE
-2.67%
ROIC
-1.49%
Gross Margin
56.97%
Oper. Margin
7.61%
Profit Margin
-3.21%
SMA20
3.38%
SMA50
1.90%
SMA200
5.07%
Trades
Shs Outstand
357.06M
Shs Float
40.05M
52W High
18.92 -7.64%
52W Low
14.44 20.98%
Volatility
2.91% 2.83%
ATR (14)
0.51
RSI (14)
58.24
Beta
0.56
Rel Volume
0.91
Avg Volume
450.68K
Volume
412,135
Perf Week
5.94%
Perf Month
3.99%
Perf Quarter
7.31%
Perf Half Y
10.43%
Perf YTD
2.28%
Perf Year
10.71%
Perf 3Y
6.85%
Perf 5Y
-
Perf 10Y
-
Prev Close
17.43
Price
17.47
Change %
0.23%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ling KarenFormer DirectorSep 28 '26Proposed Sale16.834,50075,735Sep 28 03:10 PM
Munsch FrederickSVP, Controller and CAOAug 10 '26Sale16.7852,900887,66245,831Aug 12 07:06 PM
VON ESCHENBACH ANDREW C.DirectorAug 06 '26Sale16.5012,500206,25069,792Aug 10 08:57 PM
VON ESCHENBACH ANDREW C.DirectorAug 07 '26Sale16.586,059100,45863,733Aug 10 08:57 PM
Munsch FrederickFormer OfficerAug 10 '26Proposed Sale16.7852,900887,885Aug 10 04:58 PM
VON ESCHENBACH ANDREW C.Former DirectorAug 07 '26Proposed Sale16.586,059100,430Aug 07 05:43 PM
VON ESCHENBACH ANDREW C.Former DirectorAug 06 '26Proposed Sale16.5012,500206,193Aug 06 03:11 PM
Bailey A Robert DEVP & Chief Legal OfficerMar 06 '26Buy17.1514,600250,332231,890Mar 10 05:23 PM
Eldessouky SamEVP and CFOMar 06 '26Buy17.134,00068,520403,130Mar 10 04:34 PM
SAUNDERS BRENT LCEO and Chairman of the BoardMar 06 '26Buy17.1414,700251,958966,575Mar 10 04:32 PM
Ross Thomas W. Sr.DirectorMar 03 '26Buy17.684,50079,55664,891Mar 04 04:18 PM
Alfonso EduardoDirectorMar 02 '26Buy17.904,30076,9709,555Mar 03 04:26 PM
VON ESCHENBACH ANDREW C.DirectorFeb 27 '26Buy18.304,36479,88366,450Mar 03 04:24 PM
COLLIS STEVEN HDirectorFeb 23 '26Buy17.8115,000267,15020,255Feb 24 04:23 PM
ROBERTSON RUSSEL CDirectorFeb 20 '26Buy17.904,40078,76072,407Feb 24 04:16 PM
Ling KarenDirectorFeb 19 '26Buy17.744,00070,96841,676Feb 23 04:20 PM
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.
MBAMr. Alan Waterhouse CPFA
Senior VPMr. Frederick J. Munsch
VP & Head of Investor Relations & Business InsightsMr. George Gadkowski
Chief Compliance OfficerMr. Jonathon L. Kellerman
Chief Communications OfficerMr. T.J. Crawford